Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting of MARK2, but not other MARKs, suppresses TNBC progression by inhibition of the mutant p53-driven signaling pathway.

Chinese journal of natural medicines - 1 Apr 2026

Zhang Min, Zhu Xilong, Cui Mengqian, Guan Yinan, Zhang Yong, Weiss Stephen J, Chen Jun, Yao Yongzhong, Fu Rong, Wu Zhaoqiu

Abstract excerpt

Triple-negative breast cancer (TNBC) is the most challenging breast cancer subtype to treat due to the absence of effective targeted therapies. In this study, we demonstrate that elevated expression of microtubule affinity-regulating kinase 2 (MARK2), but not other MARK family members (MARK1, MARK3, and MARK4), correlates with poor prognosis in TNBC patients. Silencing MARK2 impairs TNBC progression via...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Mutation

Share to Protein Serine-Threonine Kinases

Share to Signal Transduction

Share to Triple Negative Breast Neoplasms

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 42019995
DOI: 10.1016/S1875-5364(26)61172-7

Genes

MARK2
HBEGF
MARK1
MARK3
MARK4
THBS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting of MARK2, but not other MARKs, suppresses TNBC progression by inhibition of the mutant p53-driven signaling pathway.PMID 42019995Read ↗

High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability.Semantic proximity Read ↗

TFAP2A downregulation mediates tumor-suppressive effect of miR-8072 in triple-negative breast cancer via inhibiting SNAI1 transcriptionSemantic proximity Read ↗

The Role of UBR2 in Triple-Negative Breast Cancer and Its Implications for Immune Checkpoint Blockade TherapySemantic proximity Read ↗

Overexpression of Proteins Involved in Mitotic Progression Underlies High Proliferation and Chromosomal Instability in Androgen Receptor-Low Triple-Negative Breast CancerSemantic proximity Read ↗

MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistanceSemantic proximity Read ↗

Epigenetic mutational landscape in breast cancer: role of the histone methyltransferase gene KMT2D in triple negative tumorsSemantic proximity Read ↗

Identification of biomarker associated with Trop2 in breast cancer: implication for targeted therapySemantic proximity Read ↗

ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapySemantic proximity Read ↗

MAP3K1/MAP2K4 Mutations Drive Breast Cancer Progression by Compensating TP53 Loss via JNK2-p53-FOSL1 Axis InactivationSemantic proximity Read ↗

RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.Semantic proximity Read ↗

The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cellsSemantic proximity Read ↗

UBE2T/CDC42/CD276 signaling axis mediates brain metastasis of triple-negative breast cancer via lysosomal autophagySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.